佳醫 4104
Listed · Biotechnology and medical care72▼-0.1 (-0.14%)After close
- Prev close
- 72.1
- Volume (shares)
- 168,434
- Data time
- 2026-11-11 13:30:00
- Open
- 72.00
- High
- 72.40
- Low
- 71.70
- Prev close
- 72.10
- Volume (lots)
- 168
- Turnover
- 0.12 億
- P/E
- 15.2
- Cash yield
- 5.97%
Financial trends
Loading…
Consolidated statements; NT$100M (per-share items in NT$). Updated after each quarterly filing (MOPS). Some line items do not apply to financial companies.
Unit: 100 million TWD (EPS in TWD)Source: public data from MOPS, TWSE, TPEx and TDCC
Loading…
Figures are shown as announced, with no scoring or rating.
| Metric | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 21.57% | 21.31% | 21.63% | 20.89% | 21.57% | 21.21% | 22.38% | 21.35% |
| Operating margin | 8.11% | 7.70% | 7.30% | 8.19% | 9.24% | 8.43% | 9.93% | 9.14% |
| Net margin | 14.48% | 10.09% | 10.10% | 10.13% | 12.60% | 11.18% | 11.31% | 10.88% |
| ROE (TTM) | 9.78% | 8.96% | 8.87% | 9.12% | 9.23% | 9.24% | 8.77% | 8.85% |
| ROA (TTM) | 5.23% | 5.03% | 4.91% | 4.87% | 5.51% | 5.30% | 5.05% | 4.79% |
| EPS, quarter (TWD) | 1.65 | 1.12 | 1.13 | 0.97 | 1.41 | 1.19 | 1.18 | 1.06 |
| EPS, TTM (TWD) | 4.87 | 4.45 | 4.70 | 4.75 | 4.71 | 4.76 | 4.72 | 4.75 |
| Month | Revenue | MoM | YoY | YTD | YTD YoY |
|---|---|---|---|---|---|
| 2026-09 | 9.6 | 1.68% | 24.53% | 74.8 | 14.81% |
| 2026-08 | 9.4 | 11.96% | 32.25% | 65.2 | 13.50% |
| 2026-07 | 8.4 | -5.61% | 18.28% | 55.7 | 10.84% |
| 2026-06 | 8.9 | 27.35% | 16.07% | 47.3 | 9.61% |
| 2026-05 | 7.0 | -11.25% | -0.76% | 38.4 | 8.21% |
| 2026-04 | 7.9 | -6.06% | 14.66% | 31.3 | 10.44% |
| 2026-03 | 8.4 | 20.93% | 15.05% | 23.4 | 9.08% |
| 2026-02 | 7.0 | -13.58% | -3.44% | 15.0 | 6.00% |
| 2026-01 | 8.1 | 4.01% | 15.77% | 8.1 | 15.77% |
| 2025-12 | 7.7 | 1.23% | 0.60% | 87.9 | 2.93% |
| 2025-11 | 7.6 | 3.78% | 2.63% | 80.1 | 3.16% |
| 2025-10 | 7.4 | -4.41% | -3.37% | 72.5 | 3.21% |
Revenue in NT$100M; 12 months per page.
| Item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 23.9 | 23.4 | 22.8 | 21.9 | 21.7 | 21.5 | 22.8 | 20.6 |
| Cost of revenue | 18.7 | 18.4 | 17.9 | 17.3 | 17.0 | 16.9 | 17.7 | 16.2 |
| Gross profit | 5.2 | 5.0 | 4.9 | 4.6 | 4.7 | 4.6 | 5.1 | 4.4 |
| Operating expenses | 3.2 | 3.2 | 3.3 | 2.8 | 2.7 | 2.8 | 2.8 | 2.5 |
| Operating income | 1.9 | 1.8 | 1.7 | 1.8 | 2.0 | 1.8 | 2.3 | 1.9 |
| Non-operating items | 2.2 | 1.1 | 1.1 | 0.9 | 1.3 | 1.2 | 0.9 | 0.9 |
| Pre-tax income | 4.2 | 2.9 | 2.8 | 2.7 | 3.3 | 3.0 | 3.1 | 2.8 |
| Income tax | 0.7 | 0.6 | 0.5 | 0.5 | 0.6 | 0.6 | 0.6 | 0.5 |
| Continuing operations | 3.5 | 2.4 | 2.3 | 2.2 | 2.7 | 2.4 | 2.6 | 2.2 |
| Net income | 3.5 | 2.4 | 2.3 | 2.2 | 2.7 | 2.4 | 2.6 | 2.2 |
| Net income to parent | 3.1 | 2.1 | 1.9 | 1.9 | 2.3 | 2.0 | 1.9 | 1.7 |
| Net income to NCI | 0.4 | 0.3 | 0.4 | 0.4 | 0.4 | 0.4 | 0.7 | 0.5 |
| Other comprehensive income | -2.1 | 0.3 | 1.5 | 2.9 | -3.1 | 0.1 | 0.3 | -0.0 |
| Total comprehensive income | 1.4 | 2.7 | 3.8 | 5.1 | -0.4 | 2.5 | 2.9 | 2.2 |
| EPS (TWD) | 1.65 | 1.12 | 1.13 | 0.97 | 1.41 | 1.19 | 1.18 | 0.93 |
Amounts in NT$100M (per-share items in NT$).
| Item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|
| Current assets | 116.7 | 108.1 | 103.7 | 104.3 | 102.1 | 105.4 | 122.2 | 137.0 |
| Non-current assets | 94.8 | 86.5 | 86.1 | 83.8 | 82.2 | 82.2 | 81.5 | 82.4 |
| Total assets | 211.6 | 194.6 | 189.8 | 188.0 | 184.3 | 187.6 | 203.7 | 219.4 |
| Current liabilities | 59.9 | 63.4 | 61.9 | 64.1 | 65.7 | 68.7 | 82.9 | 102.1 |
| Non-current liabilities | 19.6 | 10.7 | 10.6 | 10.8 | 10.5 | 10.5 | 7.2 | 6.7 |
| Total liabilities | 79.5 | 74.1 | 72.5 | 74.9 | 76.3 | 79.2 | 90.1 | 108.8 |
| Share capital | 18.8 | 18.8 | 17.2 | 17.2 | 17.2 | 16.3 | 16.3 | 16.3 |
| Capital surplus | 42.5 | 42.5 | 33.9 | 33.8 | 33.8 | 33.8 | 33.8 | 33.8 |
| Retained earnings | 34.6 | 31.5 | 37.4 | 35.3 | 33.4 | 32.0 | 36.2 | 34.1 |
| Other equity | 2.2 | 3.5 | 3.4 | 2.4 | 0.4 | 3.6 | 3.3 | 3.5 |
| Equity to parent | 98.1 | 96.3 | 91.9 | 88.7 | 84.9 | 85.7 | 89.7 | 87.8 |
| Non-controlling interests | 33.9 | 24.2 | 25.3 | 24.5 | 23.2 | 22.7 | 23.9 | 22.9 |
| Total equity | 132.0 | 120.6 | 117.2 | 113.2 | 108.0 | 108.4 | 113.6 | 110.7 |
| Book value per share (TWD) | 52.10 | 51.14 | 53.58 | 51.68 | 51.93 | 52.44 | 54.90 | 53.71 |
Amounts in NT$100M (per-share items in NT$).
| Item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 3.2 | 2.2 | 2.4 | -2.5 | 1.0 | -14.5 | -18.0 | 38.7 |
| Investing cash flow | 7.1 | -0.2 | -0.2 | 0.8 | 0.3 | 1.3 | 2.5 | -3.3 |
| Financing cash flow | -7.3 | 0.1 | 2.0 | 2.5 | -5.2 | -0.9 | -2.1 | -1.7 |
| FX effect | -0.4 | 0.2 | 0.0 | 0.1 | -0.9 | 0.1 | 0.1 | 0.6 |
| Net change in cash | 2.6 | 2.3 | 4.2 | 1.0 | -4.7 | -13.9 | -17.5 | 34.3 |
| Cash, beginning | 28.5 | 28.5 | 41.9 | 41.9 | 41.9 | 41.9 | 26.1 | 26.1 |
| Cash, ending | 33.4 | 30.8 | 28.5 | 24.2 | 23.2 | 28.0 | 41.9 | 59.4 |
Amounts in NT$100M (per-share items in NT$).
| Metric | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|
| Current ratio | 194.85% | — | — | — | — | — | — | — |
| Debt ratio | 37.59% | 38.06% | 38.22% | 39.82% | 41.38% | 42.22% | 44.24% | 49.57% |
| Equity ratio | 62.41% | 61.94% | 61.78% | 60.18% | 58.62% | 57.78% | 55.76% | 50.43% |
| Equity multiplier | 1.60 | 1.61 | 1.62 | 1.66 | 1.71 | 1.73 | 1.79 | 1.98 |
| Metric | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|
| Asset turnover (TTM revenue / avg. assets) | 0.46 | 0.47 | 0.45 | 0.43 | 0.48 | 0.47 | 0.44 | 0.43 |
| Equity turnover | 0.77 | 0.78 | 0.76 | 0.79 | 0.80 | 0.81 | 0.77 | 0.77 |
Source: MOPS. For reference only; not investment advice.